5:01 PM ET
8-K
Investor Presentation
Atossa Therapeutics Investor Presentation
Atossa Therapeutics made available an updated corporate and investor presentation on September 18, 2026, highlighting its clinical development strategy for (Z)-Endoxifen. The presentation covers the company's oncology core and rare disease expansion, including Phase 2 progress in breast cancer and regulatory designations for McCune-Albright Syndrome and Duchenne Muscular Dystrophy.